Startups
Revolutionizing drug discovery through AI-powered analysis of patient-derived models for breakthrough therapeutics in cancer and regenerative medicine.
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 17, 2026 | Qbic III provides pre-seed funding to Sightera Biosciences | ANTWERP, Belgium, July 17th 2026 - Sightera Biosciences, a tech-enabled biotech company and spin-off from the University of Antwerp and Antwerp University Hospital (UZA) using generative AI to design novel small molecules currently active i... |
| Jul 17, 2026 | Sightera Biosciences closes €3M pre-seed to expand its patient-derived AI drug discovery platform | Sightera Biosciences, a Belgian techbio company using generative AI to develop novel small-molecule therapies, has raised €3 million in a pre-seed funding round led by Entourage, Anacura and QBIC. A spin-off from the University of Antwerp a... |
| Sightera Biosciences |
Reviews 0
FAQ about Sightera Biosciences
What has the press written about Sightera Biosciences?
Parsers VC has collected 4 articles mentioning Sightera Biosciences, among them “Qbic III provides pre-seed funding to Sightera Biosciences” (Jul 17, 2026) and “Sightera Biosciences closes €3M pre-seed to expand its patient-derived AI drug discovery platform” (Jul 17, 2026).
Is Sightera Biosciences still active?
Yes, Sightera Biosciences is active; its latest activity on Parsers VC dates from Jul 20, 2026.